A small study has found that CAR-T cell therapy may offer a new way to manage HIV over the long term. The approach, already used to treat certain cancers, involves engineering a patient’s own immune cells.
Researchers are repurposing the treatment for HIV after seeing positive early signs in two individuals. The modified cells appear to help control the virus without the need for constant intervention.
An Ruwaito ta hanyar AI Hoton da AI ya samar
A 47-year-old woman bedridden with autoimmune hemolytic anemia, immune thrombocytopenia, and antiphospholipid syndrome has achieved complete remission after CAR-T cell therapy at University Hospital Erlangen in Germany. Treated by Fabian Müller after nine failed therapies, she recovered rapidly and remains healthy over a year later without medication—the first simultaneous treatment of multiple autoimmune diseases with this method.
A study published on Monday in Nature Microbiology confirms long-term HIV remission in the «Oslo patient», a 62-year-old man treated for myelodysplasia via stem cell transplant from his brother carrying the CCR5 Delta 32 mutation. He has been off antiretrovirals for four years with no detectable virus. This brings the total to ten patients deemed cured this way.
An Ruwaito ta hanyar AI
Researchers have developed 3D-printed gels that mimic lymph nodes to improve the production of CAR T-cells for cancer treatment. The approach increased success rates and sped up cell growth compared with standard methods. It may help lower costs and expand access to the therapy worldwide.
A genetically engineered virus has stopped pancreatic tumors from growing in three patients in an early US clinical trial. The results come from a safety study led by researchers at the University of Minnesota.
An Ruwaito ta hanyar AI
South Africa has started rolling out the twice-yearly HIV prevention injection lenacapavir, though success depends on managing interactions with common tuberculosis medicines.